Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain
Eric Prommer, Brandy FicekDivision of Hematology/Oncology, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Scottsdale, AZ, USAAbstract: Breakthrough pain is a newly recognized pain category that was first described by Portenoy and Hagen in 1990. The term describes pain that increases in inten...
Main Authors: | Prommer E, Ficek B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-06-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/fentanyl-transmucosal-tablets-current-status-in-the-management-of-canc-a10213 |
Similar Items
-
The application of oral transmucosal fentanyl for the treatment of breakthrough pain in cancer patients
by: D V Nevzorova, et al.
Published: (2017-06-01) -
A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
by: Enno Freye
Published: (2008-12-01) -
Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
by: Darbà J, et al.
Published: (2013-12-01) -
Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets
by: Jordi Guitart, et al.
Published: (2019-06-01) -
Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study
by: Arturo Cuomo, et al.
Published: (2020-04-01)